22 June 2020 : Clinical Research
Predictive Nomogram for Midterm to Long-Term Prognosis in Patients with Papillary Renal Cell Carcinoma Based on Data from the Surveillance, Epidemiology, and End Results (SEER) Program
Haosheng Wang1BCDF, Xueliang Chen1G, Jianwu Zhao1F, Mingyang Kang1BF, Rongpeng Dong1BC, Kai Wang1B, Yang Qu1AEFG*DOI: 10.12659/MSM.921859
Med Sci Monit 2020; 26:e921859
Table 2 Univariate and multivariate Cox regression model analysis of overall survival (OS) in the training cohort.
| Variables | Univariate Cox model | P-value | Multivariate Cox model | P-value | ||
|---|---|---|---|---|---|---|
| Overall survival | Overall survival | |||||
| HR | 95% CI | HR | 95% CI | |||
| Age (years)) | ||||||
| <40 | 1 (Reference) | 1 (Reference) | ||||
| 40–49 | 1.14 | 0.781–1.664 | 0.498 | 1.335 | 0.914–1.952 | 0.135504 |
| 50–59 | 1.425 | 1.005–2.020 | 0.047* | 1.730 | 1.219–2.458 | 0.002169** |
| 60–69 | 2.025 | 1.439–2.848 | 5.08e-05*** | 2.513 | 1.783–3.542 | 1.41e-07*** |
| 70–79 | 3.319 | 2.360–4.669 | 5.57e-12*** | 3.977 | 2.821–5.607 | 3.39e-15*** |
| ≥80 | 6.045 | 4.256–8.587 | <2e-16*** | 5.964 | 4.189–8.491 | <2e-16*** |
| Gender | ||||||
| Female | 1 (Reference) | |||||
| Male | 1.06 | 0.9522–1.181 | 0.286 | |||
| Race | ||||||
| White | 1 (Reference) | |||||
| Black/African-American | 1.044 | 0.945–1.154 | 0.4 | |||
| Others | 0.8347 | 0.622–1.120 | 0.228 | |||
| Grade | ||||||
| I | 1 (Reference) | 1 (Reference) | ||||
| II | 1.057 | 0.525 | 1.093 | 0.920–1.300 | 0.312058 | |
| III | 1.59 | 1.335–1.894 | 1.95e-07*** | 1.341 | 1.120–1.605 | 0.001410** |
| IV | 3.685 | 2.925–4.643 | <2e-16*** | 1.991 | 1.562–2.536 | 2.53e-08*** |
| Unknown | 1.63 | 1.361–1.952 | 1.15e-07*** | 1.280 | 1.065–1.539 | 0.008616** |
| T | 1.63 | |||||
| T1 | 1 (Reference) | 1 (Reference) | ||||
| T2 | 1.779 | 1.564–2.024 | <2e-16*** | 1.262 | 1.103–1.444 | 0.000724*** |
| T3 | 2.737 | 2.434–3.077 | <2e-16*** | 1.549 | 1.356–1.770 | 1.20e-10*** |
| T4 | 7.103 | 5.139–9.817 | <2e-16*** | 1.405 | 0.983–2.008 | 0.062421 |
| TX | 4.824 | 3.491–6.666 | <2e-16*** | 1.649 | 1.152–2.359 | 0.006237** |
| N | ||||||
| N0 | 1 (Reference) | 1 (Reference) | ||||
| N1 | 6.383 | 5.312–7.670 | <2e-16*** | 2.182 | 1.729–2.753 | 5.01e-11*** |
| N2 | 7.936 | 6.494–9.698 | <2e-16*** | 2.207 | 1.554–2.643 | 1.83e-07*** |
| NX | 1.598 | 1.180–2.163 | 0.00242** | 1.184 | 0.834–1.679 | 0.344867 |
| M | ||||||
| M0 | 1 (Reference) | 1 (Reference) | ||||
| M1 | 11.212 | 9.711–12.945 | <2e-16*** | 3.989 | 3.268–4.869 | <2e-16*** |
| MX | 1.547 | 0.984–2.431 | 0.059 | 0.991 | 0.587–1.674 | 0.972989 |
| Surgery of primary site | ||||||
| None | 1 (Reference) | |||||
| Partial nephrectomy | 0.131 | 0.110–0.156 | 0.316 | 0.256–0.389 | <2e-16*** | |
| Total nephrectomy | 0.329 | 0.281–0.384 | 0.612 | 0.502–0.746 | 1.14e-06*** | |
| Lymphadenectomy, num | ||||||
| 0 | 1 (Reference) | 1 (Reference) | ||||
| 1–3 regional lymph nodes | 1.844 | 1.565–2.173 | 2.82e-13*** | 1.024 | 0.848–1.235 | 0.807307 |
| ≥4 regional lymph nodes | 2.138 | 5.84e-16*** | 0.987 | 0.793–1.228 | 0.906166 | |
| Chemotherapy | ||||||
| No/Unknown | 1 (Reference) | 1.778–2.570 | 1 (Reference) | |||
| Yes | 7.244 | 6.180–8.491 | <2e-16*** | 1.448 | 1.170–1.791 | 0.000662*** |
| Marital status | ||||||
| Single | 1 (Reference) | 1 (Reference) | ||||
| Married | 0.7713 | 0.704–0.846 | 3.03e-08*** | 0.752 | 0.684–0.825 | 2.17e-09*** |
| SEER – Surveillance, Epidemiology, and End Results; HR – hazard ratio; CI – confidence interval. p * p ** p *** p | ||||||